DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Phase 1

Suspended

Conditions: Carcinoma, Adrenocortical
Recurrent Adrenocortical Carcinoma (ACC)
Carcinoma, Adrenal Cortical
Recurrent Abdominal Adrenocortical Carcinoma (ACC)
Adrenocortical Carcinoma (ACC)

Interventions: Radiation: Preoperative external beam radiation therapy (EBRT)
Procedure: Surgical resection

First Posted Date: 2024-07-05

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT06487481

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase 1

Suspended

Conditions: Recurrent Myelodysplastic Syndrome
Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Myelodysplastic Syndrome
Refractory Myelodysplastic Syndrome

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Drug: Cirtuvivint
Procedure: Echocardiography Test
Drug: Decitabine and Cedazuridine
Procedure: Multigated Acquisition Scan

First Posted Date: 2024-07-03

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT06484062

Locations: 🇺🇸
Dana-Farber - Harvard Cancer Center LAO, Boston, Massachusetts, United States

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Phase 1

Not yet recruiting

Conditions: Head and Neck Tumors
Somatostatin Receptor Positive
Kidney Cancers
Small Cell Lung Cancers
Pheochromocytoma/Paragangliomas
Gastrointestinal Neuroendocrine Tumors

Interventions: Drug: 68Ga-DOTATATE
Drug: [203Pb]VMT-alpha-NET
Drug: [212Pb]VMT-alpha-NET

First Posted Date: 2024-06-28

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT06479811

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Iberdomide
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Teclistamab

First Posted Date: 2024-06-18

Last Posted Date: 2025-04-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT06465316

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

and more 1 locations

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Phase 1

Recruiting

Conditions: Unresectable Urothelial Carcinoma
Metastatic Urothelial Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Emavusertib
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Procedure: Positron Emission Tomography

First Posted Date: 2024-06-03

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT06439836

Locations: 🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Phase 1

Recruiting

Conditions: Somatostatin Receptor Positive
Gastrointestinal Neuroendocrine Tumors
Paragangliomas
Pheochromocytoma

Interventions: Drug: 68Ga-DOTATATE
Drug: [203Pb]VMT-alpha-NET
Drug: [212Pb]VMT-alpha-NET

First Posted Date: 2024-05-24

Last Posted Date: 2025-04-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT06427798

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Phase 3

Recruiting

Conditions: Unresectable Undifferentiated Pleomorphic Sarcoma
Metastatic Undifferentiated Pleomorphic Sarcoma
Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Diagnostic Imaging Testing
Drug: Doxorubicin
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Biological: Pembrolizumab

First Posted Date: 2024-05-21

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 180

Registration Number: NCT06422806

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Kaiser Permanente Dublin, Dublin, California, United States
🇺🇸
Kaiser Permanente-Fremont, Fremont, California, United States

and more 184 locations

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer
Gastroesophageal Cancer

Interventions: Drug: nivolumab
Drug: ipilimumab

First Posted Date: 2024-05-13

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT06410534

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Phase 2

Recruiting

Conditions: Carcinoma, Neuroendocrine
Tumor, Neuroendocrine
Tumors, Neuroendocrine
Neuroendocrine; Carcinoma
Small Cell; Receptors

Interventions: Drug: Belinostat
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2024-05-09

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT06406465

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Refractory Lymphoma
Refractory Multiple Myeloma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Procedure: Radionuclide Imaging
Drug: Ulixertinib

First Posted Date: 2024-05-06

Last Posted Date: 2025-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06400225

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy